RxDoctor Payments Data

Leticia Castillo Kontak, MD

Cardiovascular Disease · Round Rock, TXNPI 1891994968

Payments from drug & device makers

$7,803in general payments, 2019–2025

Across 73 payments — averaging $106.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$7K
  • Abbott$712
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$79
  • AstraZeneca$45
  • Novartis$28
  • Boston Scientific$18
  • plus $45 from 3 others

What the payments were for

  • Travel & lodging$4,39456%
  • Food & beverage$3,40944%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,803 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$124,100
Medicare patients
1,366
Services billed
2,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$356,195
XareltoRivaroxaban51$64,405
JardianceEmpagliflozin40$50,084
Repatha SureclickEvolocumab49$45,156
EntrestoSacubitril/Valsartan19$32,620
Praluent PenAlirocumab31$30,980
Metoprolol Succinate315$6,227
Atorvastatin Calcium320$4,132
Rosuvastatin Calcium249$3,940
Losartan Potassium220$3,561
Carvedilol173$2,427
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$2,248
Ezetimibe96$2,028
Warfarin Sodium99$1,687
Potassium Chloride64$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$64,40551 claims
Boehringer IngelheimJardiance$15$50,08440 claims
NovartisEntresto$28$32,62019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →